When Genzyme Corp. publicized the second that its $1 billion purchase of ILEX Oncology Inc. received with the Federal Trade Commission, the Street appeared unconcerned. Not so one arb who sold his stake that morning, April 26, and expressed surprise at the development.
To read the entire story, you must be logged in.
Please log in now or register with us.
